Akouos develops gene‑therapy treatments for inherited hearing loss, using proprietary adeno‑associated virus vectors to deliver functional copies of defective genes directly to inner‑ear cells. Their platform combines precision, minimally invasive delivery with biomarker‑driven patient selection to restore or preserve auditory function, targeting otolaryngologists, audiologists, and pharmaceutical partners.

Ambr provides a scalable metaverse development platform called xambr, which integrates essential features like avatar systems, voice and text communication, and multi-device compatibility to enhance user interaction in virtual environments. The platform addresses the challenge of creating engaging and accessible virtual worlds, enabling users to connect and experience immersive environments across various devices.

AMP provides energy management solutions specifically designed for electric vehicle (EV) charging infrastructure. The company addresses the inefficiencies in energy consumption and charging logistics, enabling seamless integration and optimization of energy resources for e-mobility.

Artiva Biotherapeutics develops AlloNK, a non-genetically modified, cryopreserved natural killer NK cell therapy designed for the treatment of autoimmune diseases and non-Hodgkin lymphoma. The company addresses the limitations of current cell therapies by providing a broadly accessible treatment option that reduces the complexities and costs associated with patient-specific manufacturing.

Arvinas uses a proprietary PROTAC discovery engine to design bifunctional molecules that recruit E3 ubiquitin ligases and trigger proteasomal degradation of disease‑relevant proteins, expanding the druggable proteome for oncology and neurodegenerative indications. The company advances clinical‑stage degraders and offers partnership models for pharmaceutical and biotechnology companies to co‑develop or license these targeted protein‑degradation therapeutics.

Audientes designs and develops self-fitting hearing aids, such as Ven, that allow users to perform hearing tests and calibrate their devices independently through built-in controls or a smartphone app. This technology addresses the challenge of accessibility and affordability in hearing solutions for individuals with mild to severe hearing loss.

Bioz offers an AI search engine specifically designed for scientific experimentation, enabling researchers to efficiently locate and evaluate relevant experimental data and methodologies. This platform addresses the challenge of information overload in scientific research by providing precise, curated insights that enhance decision-making and streamline the research process.

Calibr is an AI-powered learning experience platform that enables organizations to create and manage engaging micro-learning courses using a generative AI course authoring tool. It addresses the challenge of skill gaps by providing continuous skill assessments and analytics, allowing companies to align their learning strategies with business objectives effectively.

Chronom provides an AI-powered platform for unified cloud intelligence, mapping infrastructure, billing, and architecture into a single view. The system automates cost governance, environmental health checks, and compliance oversight to eliminate waste and boost performance. This proactive management translates cloud complexity into prioritized, actionable improvements that align technical decisions with business outcomes.

Ciara is a meeting tool specifically designed for inside sales teams, utilizing structured agendas and automated follow-ups to streamline the sales process. By reducing the time spent in meetings, Ciara helps sales representatives shorten their sales cycles significantly.

This startup provides an AI-powered life cycle assessment (LCA) tool that automates data extraction and carbon footprint calculations for products. The tool enables businesses to comply with environmental claims regulations and make data-driven sustainability decisions.

Dianthus Therapeutics is developing DNTH103, a monoclonal antibody that selectively inhibits the active form of the C1s protein in the classical complement pathway, allowing for targeted treatment of autoimmune diseases. This approach aims to reduce the frequency of administration to once every two weeks via subcutaneous injection, addressing the high treatment burden and safety concerns associated with current complement therapies.

Enliven Therapeutics develops small molecule kinase inhibitors that enhance treatment efficacy and safety for cancer patients, specifically targeting resistance mechanisms and brain metastases. The company's therapies aim to improve both survival rates and quality of life for individuals facing cancer.

Ensoma develops one-time, off-the-shelf, in vivo treatments that utilize advanced hematopoietic stem cell engineering to precisely modify cells within the hematopoietic system. This technology aims to provide durable cures for genetic, immune, and oncological diseases by addressing the limitations of traditional therapies that often require multiple treatments.

ÉTER MA provides an on-demand 3D printing supply chain that utilizes cloud-based digital warehousing to manufacture engineering parts, prototypes, and MRO components efficiently. This solution addresses the need for rapid production and inventory management in the manufacturing sector, reducing lead times and material waste.

Gen+ is a digital platform that provides leadership and meta-skills education for learners aged 9-14 and their teachers, utilizing a blended learning approach that combines online and in-person instruction. The program addresses the lack of standardized skills development in schools by equipping students with essential, transferable skills necessary for success in learning, work, and life.

Inco provides a confidentiality layer for Ethereum and other networks by utilizing Fully Homomorphic Encryption (FHE) to enable secure computations on encrypted data. This technology allows for the storage and processing of sensitive information on-chain while maintaining privacy, facilitating new use cases in payments and beyond.

Kinaset Therapeutics is developing targeted respiratory therapeutics aimed at treating severe asthma in patients with intractable diseases. Their lead asset utilizes a novel mechanism of action to improve lung function and reduce exacerbations, enhancing the quality of life for affected individuals.

Kinaset Therapeutics is developing KN-002, a non-invasive inhaled therapeutic that delivers anti-inflammatory agents directly to the lungs, targeting severe asthma regardless of the inflammation's underlying cause. This approach minimizes systemic exposure while addressing the unmet medical need for effective treatments in patients with intractable respiratory diseases.

Letta provides a platform for building memory‑first AI agents that retain context and continuously learn from experience. Developers use the Letta Code CLI and TypeScript SDK to create persistent, identity‑driven agents that can run locally or in the cloud, version their knowledge in a git‑backed repository, and be teleported across devices while integrating any LLM API.

Lex is a writing tool that integrates AI-driven feedback and context-aware editing to enhance clarity and creativity in writing. It addresses writer's block and inefficiencies by providing real-time collaboration, version control, and customizable prompts, enabling users to produce high-quality content more effectively.

Lula provides a property maintenance platform that connects property managers with a network of vetted contractors, significantly reducing maintenance response times. By streamlining the maintenance process, Lula decreases the time spent on property upkeep by nearly 60%, enhancing operational efficiency for property managers and their tenants.

MapLight Therapeutics utilizes optogenetics, STARmap, and transcriptomics to identify and target specific neural circuits involved in brain disorders. The company aims to develop therapeutics that provide effective treatment options for conditions such as schizophrenia, Alzheimer’s disease psychosis, and autism spectrum disorder, addressing the limitations of current therapies.

MRDVS develops 3D cameras utilizing Time-of-Flight and structured light technology to provide high-resolution point cloud data for precise object recognition and navigation. Their solutions enhance robotic capabilities in applications such as obstacle avoidance and automated material handling, addressing the need for accurate perception in complex environments.